Mirae Asset Global Investments Co. Ltd. Has $86,000 Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)

Mirae Asset Global Investments Co. Ltd. increased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 21.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,983 shares of the company’s stock after purchasing an additional 350 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Vera Therapeutics were worth $86,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Eastern Bank acquired a new stake in shares of Vera Therapeutics in the third quarter worth $2,477,000. Handelsbanken Fonder AB lifted its position in Vera Therapeutics by 19.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the company’s stock worth $610,000 after acquiring an additional 2,200 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Vera Therapeutics by 117.5% during the third quarter. SG Americas Securities LLC now owns 9,354 shares of the company’s stock valued at $413,000 after acquiring an additional 5,053 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Vera Therapeutics in the second quarter valued at about $1,353,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vera Therapeutics in the second quarter worth about $163,000. Institutional investors own 99.21% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on VERA. JPMorgan Chase & Co. increased their target price on Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Guggenheim boosted their target price on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Scotiabank started coverage on shares of Vera Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price objective on shares of Vera Therapeutics in a report on Tuesday, October 1st. Finally, Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $53.56.

Vera Therapeutics Stock Up 3.1 %

NASDAQ VERA opened at $45.17 on Tuesday. Vera Therapeutics, Inc. has a 1-year low of $9.88 and a 1-year high of $50.78. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15. The stock’s 50 day moving average is $40.65 and its two-hundred day moving average is $38.90. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -20.44 and a beta of 1.03.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Equities analysts forecast that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 14,471 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $39.76, for a total transaction of $575,366.96. Following the sale, the chief executive officer now directly owns 322,667 shares of the company’s stock, valued at approximately $12,829,239.92. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total value of $49,445.77. Following the transaction, the director now owns 160,376 shares of the company’s stock, valued at approximately $6,737,395.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marshall Fordyce sold 14,471 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $39.76, for a total value of $575,366.96. Following the sale, the chief executive officer now owns 322,667 shares in the company, valued at $12,829,239.92. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,398 shares of company stock valued at $4,376,163 in the last ninety days. Insiders own 21.70% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.